idebenone has been researched along with Left Ventricular Hypertrophy in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors carried out a 1-year, randomized, placebo-controlled trial of idebenone in 29 patients with Friedreich ataxia." | 5.10 | Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. ( Di Donato, S; Fiorentini, C; Marano, L; Mariotti, C; Solari, A; Torta, D, 2003) |
| "Low-quality evidence from two small, published, randomised controlled trials neither support nor refute an effect from antioxidants (idebenone, or a combination of coenzyme Q10 and vitamin E) on the neurological status of people with Friedreich ataxia, measured with a validated neurological rating scale." | 4.93 | Pharmacological treatments for Friedreich ataxia. ( Brassington, R; Fahey, M; Kearney, M; Orrell, RW; Pandolfo, M, 2016) |
| "More than 10 studies used idebenone in the treatment of Friedreich ataxia but only one small RCT, with 29 participants, using the synthetic antioxidant idebenone 5 mg/kg, fulfilled the selection criteria for this review." | 4.88 | Antioxidants and other pharmacological treatments for Friedreich ataxia. ( Fahey, M; Kearney, M; Orrell, RW; Pandolfo, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kearney, M | 2 |
| Orrell, RW | 2 |
| Fahey, M | 2 |
| Brassington, R | 1 |
| Pandolfo, M | 2 |
| Rinaldi, C | 1 |
| Tucci, T | 1 |
| Maione, S | 1 |
| Giunta, A | 1 |
| De Michele, G | 1 |
| Filla, A | 2 |
| Lagedrost, SJ | 1 |
| Sutton, MS | 1 |
| Cohen, MS | 1 |
| Satou, GM | 1 |
| Kaufman, BD | 1 |
| Perlman, SL | 1 |
| Rummey, C | 1 |
| Meier, T | 1 |
| Lynch, DR | 1 |
| Moss, AJ | 1 |
| Mariotti, C | 1 |
| Solari, A | 1 |
| Torta, D | 1 |
| Marano, L | 1 |
| Fiorentini, C | 1 |
| Di Donato, S | 1 |
| Buyse, G | 1 |
| Mertens, L | 1 |
| Di Salvo, G | 1 |
| Matthijs, I | 1 |
| Weidemann, F | 1 |
| Eyskens, B | 1 |
| Goossens, W | 1 |
| Goemans, N | 1 |
| Sutherland, GR | 1 |
| Van Hove, JL | 1 |
| Rustin, P | 1 |
| Bonnet, D | 1 |
| Rötig, A | 1 |
| Munnich, A | 1 |
| Sidi, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients[NCT00537680] | Phase 3 | 70 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | g/m2 (Mean) |
|---|---|
| Mid Dose Idebenone | -3.06 |
| High Dose Idebenone | -2.56 |
| Placebo | -1.26 |
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | cm (Mean) |
|---|---|
| Mid Dose Idebenone | -0.032 |
| High Dose Idebenone | 0.007 |
| Placebo | 0.010 |
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | cm (Mean) |
|---|---|
| Mid Dose Idebenone | -0.014 |
| High Dose Idebenone | 0.021 |
| Placebo | 0.063 |
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | cm (Mean) |
|---|---|
| Mid Dose Idebenone | -0.018 |
| High Dose Idebenone | -0.004 |
| Placebo | -0.038 |
"To compare the efficacy of 6 months' treatment with 2 different doses of idebenone with that of placebo on Activities of Daily Living (ADL) assessed by the ADL scale of the Friedreich's Ataxia Rating Scale (FARS)~score 0 to 36, higher score indicates greater impairment" (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | ADL points (Mean) |
|---|---|
| Mid Dose Idebenone | 0.2 |
| High Dose Idebenone | 0.6 |
| Placebo | 1.0 |
"To compare the efficacy of 6 months' treatment with 2 different doses of idebenone with that of placebo on neurological function as assessed by the Friedreich's Ataxia Rating Scale (FARS)~FARS consists of a 25 manoeuvre exam along with 4 quantitative performance measures. The neurological exam covers bulbar function, upper limb coordination, lower limb coordination, peripheral nervous system function, deep tendon reflexes, stability and gait. The use of FARS has been recently validated as a sensitive scale for this population.~The FARS exam scores can be added to make a total score ranging from 0 to 159. A higher score indicates a greater level of disability.~Calculation details FARS score at week 24 minus FARS score baseline" (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | FARS score (Mean) |
|---|---|
| Mid Dose Idebenone | -1.6 |
| High Dose Idebenone | -1.2 |
| Placebo | 0.6 |
"To compare the efficacy of 3 months' treatment with 2 different doses of idebenone with that of placebo on neurological impairment as assessed by the International Cooperative Ataxia Rating Scale (ICARS)~International Cooperative Ataxia Rating Scale (ICARS):~ICARS consists of a one-hundred-point semi-quantitative scale based upon 19 simple testing manoeuvres compartmentalized into postural and stance disorders, limb ataxia, dysarthria and oculomotor disorders and has been previously used in this patient population with good inter-rater reliability.~Minimum score: 0, maximum score 100, higher score indicates greater impairment~Calculation details: ICARS score at week 12 minus ICARS score baseline" (NCT00537680)
Timeframe: baseline and 12 weeks
| Intervention | ICARS points (Mean) |
|---|---|
| Mid Dose Idebenone | -1.5 |
| High Dose Idebenone | -1.6 |
| Placebo | -3.0 |
"International Cooperative Ataxia Rating Scale (ICARS):~ICARS consists of a one-hundred-point semi-quantitative scale based upon 19 simple testing manoeuvres compartmentalized into postural and stance disorders, limb ataxia, dysarthria and oculomotor disorders and has been previously used in this patient population with good inter-rater reliability.~Minimum score: 0, maximum score 100, higher score indicates greater impairment~Calculation details: ICARS score at week 24 minus ICARS score baseline" (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | ICARS points (Mean) |
|---|---|
| Mid Dose Idebenone | -2.5 |
| High Dose Idebenone | -2.4 |
| Placebo | -1.3 |
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | % change (Mean) |
|---|---|
| Mid Dose Idebenone | -4.5 |
| High Dose Idebenone | -4.9 |
| Placebo | -1.7 |
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | % change (Mean) |
|---|---|
| Mid Dose Idebenone | -3.32 |
| High Dose Idebenone | 1.53 |
| Placebo | 2.65 |
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 24 weeks
| Intervention | % change (Mean) |
|---|---|
| Mid Dose Idebenone | 1.3 |
| High Dose Idebenone | 2.6 |
| Placebo | 7.8 |
To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography (NCT00537680)
Timeframe: baseline and 6 months
| Intervention | % change (Mean) |
|---|---|
| Mid Dose Idebenone | -0.075 |
| High Dose Idebenone | 0.12 |
| Placebo | -3.04 |
2 reviews available for idebenone and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Pharmacological treatments for Friedreich ataxia.
Topics: Antioxidants; Friedreich Ataxia; Heart; Humans; Hypertrophy, Left Ventricular; Randomized Controlled | 2016 |
Antioxidants and other pharmacological treatments for Friedreich ataxia.
Topics: Antioxidants; Friedreich Ataxia; Humans; Hypertrophy, Left Ventricular; Randomized Controlled Trials | 2012 |
3 trials available for idebenone and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA).
Topics: Adolescent; Antioxidants; Cardiomyopathy, Hypertrophic; Child; Clinical Trials, Phase III as Topic; | 2011 |
Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial.
Topics: Adolescent; Adult; Benzoquinones; Cardiomyopathy, Hypertrophic; Child; Erythrocytes; Female; Frataxi | 2003 |
Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring.
Topics: Adolescent; Adult; Benzoquinones; Cardiomyopathy, Hypertrophic; Child; Erythrocytes; Female; Frataxi | 2003 |
3 other studies available for idebenone and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Low-dose idebenone treatment in Friedreich's ataxia with and without cardiac hypertrophy.
Topics: Adult; Analysis of Variance; Antioxidants; Cohort Studies; Echocardiography; Female; Follow-Up Studi | 2009 |
Idebenone for treatment of Friedreich's ataxia?
Topics: Benzoquinones; Double-Blind Method; Free Radical Scavengers; Friedreich Ataxia; Humans; Hypertrophy, | 2003 |
Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial.
Topics: Antioxidants; Benzoquinones; Cardiotonic Agents; Clinical Trials as Topic; Friedreich Ataxia; Humans | 2004 |